Experience

Davis Polk advised the joint book-running managers for a $50 million public offering of common stock by Ardelyx, Inc. The common stock is listed on the NASDAQ Global Market under the…

Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common stock of Coherus BioSciences, Inc. Based in Redwood City, California,…

Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Omnicell, Inc. of its shares of common stock for up to an aggregate amount of $125…

Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of 2.250% senior notes due 2021. …

Davis Polk advised the administrative agent in connection with a $3.1 billion best-efforts financing comprised of a $1 billion senior secured term loan A facility, a $1.6 billion senior…

Davis Polk advised the representatives of the several underwriters in connection with the $103.5 million initial public offering of common stock of Kala Pharmaceuticals, Inc. The…

Davis Polk advised the representatives of the underwriters, in connection with the offering of €1 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised…